Ding F, Chen RY, Hou J, Guo J, Dong TY. Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer. World J Clin Cases 2022; 10(12): 3698-3708 [PMID: 35647172 DOI: 10.12998/wjcc.v10.i12.3698]
Corresponding Author of This Article
Tian-Yi Dong, MD, Chief Doctor, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324 Jingwuweiqi Road, Jinan 250021, Shandong Province, China. shandongyiyi2021@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Apr 26, 2022; 10(12): 3698-3708 Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3698
Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
Feng Ding, Ru-Yue Chen, Jun Hou, Jing Guo, Tian-Yi Dong
Feng Ding, Department of General Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong Province, China
Ru-Yue Chen, Tian-Yi Dong, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
Jun Hou, Jing Guo, Department of Anesthesiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong Province, China
Author contributions: Dong TY and Ding F designed this retrospective study; Dong TY and Chen RY wrote this paper; Dong TY, Chen RY, Hou J, Guo J and Ding F were responsible for sorting the data.
Institutional review board statement: The study was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University (SWYX: No.2021-223).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: No conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tian-Yi Dong, MD, Chief Doctor, Department of Breast and Thyroid Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No. 324 Jingwuweiqi Road, Jinan 250021, Shandong Province, China. shandongyiyi2021@163.com
Received: November 24, 2021 Peer-review started: November 24, 2021 First decision: December 9, 2021 Revised: December 26, 2021 Accepted: March 5, 2022 Article in press: March 5, 2022 Published online: April 26, 2022 Processing time: 148 Days and 1.4 Hours
ARTICLE HIGHLIGHTS
Research background
Patients with triple-negative breast cancer (TNBC) have relatively high recurrence and transfer rates during the operation and 3 years after postoperative adjuvant chemotherapy.
Research motivation
This study identified the additional effective treatments to improve patient prognosis.
Research objectives
This study aimed to explore and discuss the effects and prognostic factors of neoadjuvant chemotherapy in TNBC.
Research methods
Total 118 patients diagnosed with TNBC from January 2016 to January 2020 in our hospital were selected and divided into the observation (n = 60) and control (n = 58) groups according to therapeutic regimen. The control group received routine chemotherapy, and the observation group received neoadjuvant chemotherapy.
Research results
The short-term curative effect of the observation group was significantly better than that of the control group, and the median survival time of the observation group was significantly longer than that of the control group (P < 0.05). The epirubicin-paclitaxel regimen can significantly reduce the levels of tumor markers and cytokines in patients with good therapeutic effect.
Research conclusions
Neoadjuvant chemotherapy for TNBC treatment can achieve good curative effects. Moreover, tumor-node-metastasis stage, differentiation degree, lymph node metastasis, karyopherin A2 and SRY-related HMG box-2 expressions, and treatment plan are prognostic factors of patients with TNBC.
Research perspectives
Next, we will investigate the mechanism of neoadjuvant chemotherapy for TNBC.
